CVS Health Corporation (NYSE:CVS) Director Richard J. Swift sold 2,500 shares of the firm’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $79.62, for a total value of $199,050.00. Following the transaction, the director now owns 3,258 shares of the company’s stock, valued at $259,401.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
CVS Health Corporation (NYSE:CVS) traded down 1.56% on Friday, hitting $77.66. The stock had a trading volume of 5,005,371 shares. CVS Health Corporation has a 12 month low of $69.30 and a 12 month high of $98.44. The stock has a market cap of $78.95 billion, a P/E ratio of 15.47 and a beta of 0.91. The company’s 50 day moving average is $78.68 and its 200-day moving average is $78.94.
CVS Health Corporation (NYSE:CVS) last issued its earnings results on Tuesday, August 8th. The pharmacy operator reported $1.33 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.02. CVS Health Corporation had a return on equity of 17.47% and a net margin of 2.93%. The firm had revenue of $45.69 billion for the quarter, compared to the consensus estimate of $45.36 billion. During the same quarter in the prior year, the business earned $1.32 earnings per share. The company’s revenue was up 4.5% compared to the same quarter last year. Analysts forecast that CVS Health Corporation will post $5.88 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, August 3rd. Stockholders of record on Monday, July 24th were paid a $0.50 dividend. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.58%. CVS Health Corporation’s payout ratio is 39.92%.
TRADEMARK VIOLATION WARNING: “Insider Selling: CVS Health Corporation (CVS) Director Sells 2,500 Shares of Stock” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/08/19/insider-selling-cvs-health-corporation-cvs-director-sells-2500-shares-of-stock.html.
Several hedge funds have recently modified their holdings of CVS. Jackson Grant Investment Advisers Inc. increased its stake in shares of CVS Health Corporation by 0.6% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 2,881 shares of the pharmacy operator’s stock worth $232,000 after buying an additional 18 shares during the last quarter. Keel Point LLC increased its stake in shares of CVS Health Corporation by 0.7% in the first quarter. Keel Point LLC now owns 3,296 shares of the pharmacy operator’s stock worth $259,000 after buying an additional 22 shares during the last quarter. First City Capital Management Inc. increased its stake in shares of CVS Health Corporation by 0.3% in the first quarter. First City Capital Management Inc. now owns 12,771 shares of the pharmacy operator’s stock worth $1,003,000 after buying an additional 40 shares during the last quarter. Elefante Mark B increased its stake in shares of CVS Health Corporation by 0.7% in the second quarter. Elefante Mark B now owns 6,400 shares of the pharmacy operator’s stock worth $515,000 after buying an additional 45 shares during the last quarter. Finally, Traynor Capital Management Inc. increased its stake in shares of CVS Health Corporation by 1.3% in the second quarter. Traynor Capital Management Inc. now owns 3,676 shares of the pharmacy operator’s stock worth $290,000 after buying an additional 48 shares during the last quarter. Hedge funds and other institutional investors own 82.31% of the company’s stock.
Several equities analysts have recently weighed in on CVS shares. Tigress Financial assumed coverage on CVS Health Corporation in a report on Thursday, April 27th. They set a “buy” rating for the company. Vetr cut CVS Health Corporation from a “buy” rating to a “hold” rating and set a $85.78 price objective on the stock. in a research report on Thursday, April 27th. Evercore ISI reaffirmed an “outperform” rating and set a $88.00 price objective (up from $87.00) on shares of CVS Health Corporation in a research report on Wednesday, May 3rd. ValuEngine cut CVS Health Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $82.00 price objective on shares of CVS Health Corporation in a research report on Friday, June 9th. Nine research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $91.24.
CVS Health Corporation Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
